Welcome to our dedicated page for MANGOCEUTICALS SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mangoceuticals, Inc. filings document a Nasdaq Capital Market-listed wellness telemedicine company, its MangoRx and PeachesRx brands, and securities issued to finance corporate operations. The company’s regulatory record includes Form 8-K reports on product communications, MGX-0024 data, branded GLP-1 program disclosures, litigation-related press releases, Nasdaq listing-rule notices and equity-compensation actions.
Registration statements and amendments describe the company’s securities offerings, capital structure, financial statements and risk disclosures. Other filings address common stock, warrants and pre-funded warrants, board and committee approvals, executive compensation arrangements, material events and forward-looking statement qualifications tied to Mangoceuticals’ telehealth platform, wellness products and public-company obligations.
MANGOCEUTICALS, INC. Chief Executive Officer Jacob D. Cohen reported an option repricing approved by the Board and its Compensation Committee. On the effective date, existing stock options covering 50,000, 83,333 and 2,000,000 shares of common stock were surrendered to the company and replaced on a one-for-one basis.
The replacement options cover the same total number of underlying shares but now carry a new exercise price of $0.45 per share, which the company states exceeded the Nasdaq closing price on the effective date. All other terms of the options, including prior vesting schedules, remain unchanged. Following these changes, Cohen also reports direct holdings of 200,000 and 605,000 shares of common stock.
Mangoceuticals, Inc. approved a repricing of stock options held by Chief Executive Officer and Chairman Jacob Cohen as of March 16, 2026. The exercise price on options for 50,000 shares originally priced at $16.50, 83,333 shares at $4.80, and 2,000,000 shares at $2.30 was reset to $0.45 per share, which was the closing price of the company’s common stock on the effective date. Mr. Cohen recused himself, and the remaining disinterested directors approved the change upon recommendations from the compensation and audit committees.
The company also filed a civil lawsuit in Texas state court against its former technology consulting and software development firm, Clarity Ventures, Inc., seeking damages exceeding $73 million, exclusive of interest, costs, and attorneys’ fees. Mangoceuticals alleges Clarity failed to deliver a fully functional, HIPAA-compliant ERP and eCommerce platform, while Clarity denies these allegations and has asserted counterclaims relating to alleged unpaid invoices. Mangoceuticals states that it now operates on an internally developed telehealth and eCommerce platform and that all litigation allegations and counterclaims remain subject to the court process.
Mangoceuticals, Inc. reported new data on its proprietary antiviral compound MGX-0024 for use in poultry. In three commercial field trials in India covering approximately 29,000 broiler chickens, birds receiving MGX-0024 in drinking water had zero respiratory-related mortality, despite historical and neighboring flock data suggesting about 50% respiratory-related deaths.
A separate controlled government study using a highly pathogenic H5N1 strain found that birds pre-treated with MGX-0024 for 48 hours showed up to a 60% reduction in mortality versus untreated controls, longer time to death, and limited viral shedding. The company emphasizes these results are preliminary, subject to further validation, regulatory review, and not yet approved for veterinary use.
Mangoceuticals, Inc. reported early traction for its newly launched all-inclusive injectable testosterone replacement therapy (TRT) program, priced at $99 per month. The offer covers doctor visits, lab work and prescribed medication, delivered via the company’s telemedicine platform under the MangoRx brand.
The company highlighted that month-over-month sales for the injectable TRT program have risen 336% since its mid-December launch, while customer acquisition costs declined 54%. Management views TRT as the primary growth focus and plans to expand both injectable and oral offerings as part of a broader men’s health platform.
Mangoceuticals, Inc. reported that on February 4, 2026 it received a deficiency notice from Nasdaq because its common stock bid price had closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar day grace period, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Nasdaq’s notice does not immediately affect the listing or trading of the stock, and Mangoceuticals plans to monitor its share price and consider options to address the deficiency.
Mangoceuticals, Inc. is registering 2,640,178 shares of common stock for resale by existing investors. The shares consist of 1,930,502 shares issuable upon exercise of warrants with a $1.4245 per share exercise price and 709,676 already issued shares that were sold at $1.55 per share to accredited investors.
The company is not selling any shares in this offering and will not receive proceeds from resale by the selling stockholders; it will receive cash only if the warrants are exercised, which it plans to use for general working capital. Mangoceuticals operates the MangoRX telehealth platform, offering compounded men’s wellness products and an FDA‑approved oral testosterone therapy, and relies on related-party pharmacy Epiq Scripts for compounding and fulfillment. Its common stock trades on Nasdaq under the symbol MGRX, with a last reported price of $0.537 per share on January 22, 2026.
Mangoceuticals, Inc. has filed a Form S-1 registering up to 2,640,178 shares of common stock for resale by existing stockholders. The shares consist of 1,930,502 shares issuable upon exercise of common stock purchase warrants at an exercise price of $1.4245 per share and 709,676 already issued shares that were sold to accredited investors at $1.55 per share. The company is not selling any shares itself in this offering and will not receive proceeds from stockholder resales, but would receive cash if holders exercise the warrants, which it plans to use for general working capital. The selling stockholders may sell their shares over time in various types of public or private transactions. Mangoceuticals’ common stock trades on Nasdaq under the symbol “MGRX”, and the last reported price on January 12, 2026 was $0.785 per share.
Mangoceuticals, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/15/2025, the CFO sold 3,333 shares of the company’s common stock at a price of $1.1653 per share. After this sale, the CFO beneficially owned 120,000 shares, held directly. The filing reflects a routine update of the officer’s ownership position and does not list any derivative securities transactions.
Mangoceuticals, Inc. director reports stock sale in Form 4 filing. A board member of Mangoceuticals, Inc. (MGRX) disclosed the sale of 125,000 shares of common stock on 11/19/2025, reported under transaction code "S" for a sale. The weighted average sale price was $1.223 per share.
These shares were sold in multiple trades at prices ranging from $1.195 to $1.2465 per share. Following this transaction, the reporting person beneficially owns 3,334 shares of Mangoceuticals common stock in direct ownership.